Spots Global Cancer Trial Database for advanced non small cell lung cancer
Every month we try and update this database with for advanced non small cell lung cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | NCT00714246 | Non Small Cell ... | Bortezomib Carboplatin Docetaxel | 18 Years - 90 Years | Milton S. Hershey Medical Center | |
| Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG | NCT06107374 | Advanced Non Sm... | [18F]F-AraG | 18 Years - | CellSight Technologies, Inc. | |
| Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients | NCT03351361 | Advanced Non Sm... | Nivolumab + Ipi... Chemotherapy | 18 Years - | Rennes University Hospital | |
| Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling | NCT02407327 | Advanced Non Sm... | 18 Years - 80 Years | Istituto Oncologico Veneto IRCCS | ||
| Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer | NCT01631136 | Advanced Non Sm... | Cisplatin Pemetrexed Cisplatin Gemcitabine | 18 Years - 70 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Long-Term Follow-Up Study of Patients Receiving ATL001 | NCT04785365 | Melanoma Advanced Non Sm... | Biological: ATL... | 18 Years - | Achilles Therapeutics UK Limited | |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients | NCT03351361 | Advanced Non Sm... | Nivolumab + Ipi... Chemotherapy | 18 Years - | Rennes University Hospital | |
| Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC | NCT04886401 | Advanced Non Sm... | - | University Hospital, Brest | ||
| Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer | NCT04755738 | Advanced Non Sm... | Almonertinib pl... | 18 Years - 80 Years | Qianfoshan Hospital | |
| Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | NCT03326752 | Advanced Non Sm... | DV281 Breath Actuated... DV281 (RP2D) Approved Anti-P... | 18 Years - | Dynavax Technologies Corporation | |
| Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC | NCT00250978 | Carcinoma, Non-... | bevacizumab wit... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| D-0316 First Time in Patients Ascending Dose Study | NCT03452150 | Advanced Non Sm... | D-0316 | 18 Years - 75 Years | InventisBio Co., Ltd | |
| Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | NCT05777603 | Advanced Non Sm... | aerosolized azt... aerosolized van... pembrolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics | NCT02143466 | Advanced Non Sm... | Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part B - AZD929... Part B - AZD929... Part B - AZD929... Part C - AZD609... Part C - AZD929... Part D - AZD929... | 18 Years - 130 Years | AstraZeneca | |
| Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | NCT05004974 | Advanced Non Sm... | Sintilimab Pemigatinib | 18 Years - | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | |
| Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | NCT05777603 | Advanced Non Sm... | aerosolized azt... aerosolized van... pembrolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer | NCT04755738 | Advanced Non Sm... | Almonertinib pl... | 18 Years - 80 Years | Qianfoshan Hospital | |
| Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer | NCT00510445 | Lung Cancer | Imetelstat Sodi... | 18 Years - | Geron Corporation | |
| Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) | NCT02157883 | Advanced Non Sm... Advanced (Inope... | Pharmacokinetic... AZD9291 Itraconazole | 18 Years - 99 Years | AstraZeneca | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | NCT04032847 | Advanced Non Sm... | ATL001 Pembrolizumab | 18 Years - 75 Years | Achilles Therapeutics UK Limited | |
| Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | NCT00714246 | Non Small Cell ... | Bortezomib Carboplatin Docetaxel | 18 Years - 90 Years | Milton S. Hershey Medical Center | |
| Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer | NCT00072631 | Advanced Non Sm... Failed Prior Ch... | Tarceva (Tradem... | 18 Years - | Astellas Pharma Inc | |
| Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | NCT04940325 | Metastatic Lung... | DS-1062a | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) | NCT02157883 | Advanced Non Sm... Advanced (Inope... | Pharmacokinetic... AZD9291 Itraconazole | 18 Years - 99 Years | AstraZeneca | |
| Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | NCT04239443 | Advanced Non Sm... Uterine Cancer Soft Tissue Sar... | PD-1 inhibitor Apatinib | 18 Years - 70 Years | Hunan Cancer Hospital | |
| D-0316 First Time in Patients Ascending Dose Study | NCT03452150 | Advanced Non Sm... | D-0316 | 18 Years - 75 Years | InventisBio Co., Ltd | |
| Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer | NCT03652857 | Advanced Non Sm... | Apatinib Combin... | 18 Years - | Hunan Province Tumor Hospital | |
| Lifei Xiaoji Wan in Treatment of Advanced NSCLC | NCT06406166 | Advanced Non Sm... | Lifei Xiaoji Wa... Conventional tr... | 18 Years - 80 Years | Henan University of Traditional Chinese Medicine | |
| Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer | NCT04144608 | Advanced Non Sm... | Toripalimab com... | 18 Years - 70 Years | Hunan Province Tumor Hospital | |
| Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC | NCT04886401 | Advanced Non Sm... | - | University Hospital, Brest | ||
| Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer | NCT04755738 | Advanced Non Sm... | Almonertinib pl... | 18 Years - 80 Years | Qianfoshan Hospital | |
| Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer | NCT01631136 | Advanced Non Sm... | Cisplatin Pemetrexed Cisplatin Gemcitabine | 18 Years - 70 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | NCT00714246 | Non Small Cell ... | Bortezomib Carboplatin Docetaxel | 18 Years - 90 Years | Milton S. Hershey Medical Center | |
| Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC | NCT04886401 | Advanced Non Sm... | - | University Hospital, Brest | ||
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC | NCT00250978 | Carcinoma, Non-... | bevacizumab wit... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | NCT04239443 | Advanced Non Sm... Uterine Cancer Soft Tissue Sar... | PD-1 inhibitor Apatinib | 18 Years - 70 Years | Hunan Cancer Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
